< View all reports

Microbiome Analysis Report

Microbiome-Targeted Therapeutics in Immunology

Flares in gastrointestinal and dermatology indications are characterized by a shift in the proportion of bacterial species in either the gut or skin microbiome. Our microbiome analysis report provides a deep dive into the microbiome space.

GlobalData’s Microbiome Analysis report combines key opinion leader and payer insight with in-house analyst expertise to deliver a deep analysis into the microbiome space in immunology. It focuses on the development of therapies targeting the skin microbiome for treatment of acne, atopic dermatitis and psoriasis and on development of therapies targeting the gut microbiome for treatment of Crohn’s disease, UC, and IBS.

Stay ahead of the competition and get ahead with our report.

  • Report Scope:
  • Promising late-stage products and early-stage pipeline by indication
  • Leading industry companies by indication
  • Clinical trial breakdown by phase/indication and trial design by indication
  • Opportunities and challenges for gastrointestinal indications
  • Market potential estimate of late-stage therapies and key launch dates

Small biotech leads the way in microbiome-targeted therapeutics; however large pharma companies such as J&J have made it a priority to partner with biotech companies and academic labs to further development of microbiome-targeted therapeutics in immunology.

There are 10 pipeline therapies in clinical development targeting the gut microbiome for treatment of Crohn’s Disease, UC and IBS. For treatment of acne, AD and PsO however, there are only three pipeline therapies in clinical development targeting the skin microbiome.

Purchase Today

Single user $ 7,995

Buy Now


+44 (0) 161 359 5813

Not ready to buy yet? Download our free report series guide on Microbiome Analysis

I consent to GlobalData collecting my details provided via this form.

You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you. Please check our GlobalData Privacy Policy to see how we protect and manage your submitted data.